SOUTH SAN FRANCISCO, Calif.,
Jan. 9, 2020 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced
that Raul Rodriguez, the company's
president and CEO, is scheduled to present a company overview at
the 38th Annual J.P. Morgan Healthcare Conference on
Thursday, January 16, 2020 at
7:30am PT in San Francisco, CA.
To access the live and subsequently archived webcast, go to the
Investor Relations section of the company's website at
www.rigel.com. Please connect to Rigel's website several minutes
prior to the start of the live webcast to ensure adequate time for
any software download that may be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE® (fostamatinib disodium hexahydrate), the only
oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of
adult patients with chronic immune thrombocytopenia who have had an
insufficient response to a previous treatment. Rigel's current
clinical programs include a Phase 3 study of fostamatinib in
autoimmune hemolytic anemia (AIHA); a recently completed Phase 1
study of R8351, a proprietary molecule from its
interleukin receptor associated kinase (IRAK) program; and an
ongoing Phase 1 study of R5521, a proprietary molecule
from its receptor-interacting protein kinase (RIP1) inhibitor
program. In addition, Rigel has product candidates in clinical
development with partners Aclaris Therapeutics, AstraZeneca,
BerGenBio ASA, and Daiichi Sankyo.
1The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
Please see www.TAVALISSE.com for full Prescribing
Information.
IR Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-at-the-38th-annual-jp-morgan-healthcare-conference-300984085.html
SOURCE Rigel Pharmaceuticals, Inc.